Active — Not RecruitingNot Applicable

Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy

United States26 participantsStarted 2019-04-23

Plain-language summary

This trial studies how well a diet high in magnesium works in preventing low blood magnesium levels (hypomagnesemia) in patients with ovarian cancer receiving carboplatin chemotherapy. Hypomagnesemia is a common side effect of carboplatin-containing chemotherapy. A magnesium rich diet may increase the levels of magnesium in the blood and help prevent hypomagnesemia resulting from carboplatin chemotherapy.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with previously untreated ovarian cancer. * Receiving carboplatin-containing chemotherapy of at least 6 consecutive cycles. * Able to tolerate an oral diet. Exclusion Criteria: * Prior platinum-based chemotherapy. * Serum creatinine level \> 1.4 mg/dL prior to treatment. * Artificial nutrition (e.g. Ensure or Boost) accounts for \> 50% of total calorie intake.

What they're measuring

Patient retention rate

Timeframe: Up to 2 years

Dietary adherence rate

Timeframe: Up to 2 years

Trial details

NCT IDNCT04310826

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04-01

View on ClinicalTrials.gov More Ovarian Carcinoma trials